SCHEMBL20779791

SCHEMBL20779791

CNS(=O)(=O)c1ccc(Nc2cccc(C(F)(F)F)c2)c(-c2ccnc(N)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.55
▸ TEAD1 P28347 1/20 0.49
▸ YAP1 P46937 1/20 0.49
▸ TNNI3K Q59H18 8/20 0.48
▸ IDH2 P48735 3/20 0.47
▸ BRAF P15056 2/20 0.47
▸ EGFR P00533 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ GAA P10253 2/20 0.44
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ AR P10275 1/20 0.42
▸ SCN9A Q15858 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ FFAR1 O14842 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ CCNB1 P14635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29901821 1.00 MAPT (0.55) MAPTTEAD1YAP1TNNI3KIDH2
SCHEMBL20779731 0.89 TEAD1 (0.62) MAPTTEAD1YAP1TNNI3KSCN9A
SCHEMBL29901791 0.89 TEAD1 (0.62) MAPTTEAD1YAP1TNNI3KSCN9A
SCHEMBL20779895 0.81 MAPT (0.44) MAPTIDH2EGFRKDM4EGAA
SCHEMBL21091049 0.80 MAPT (0.44) MAPTEGFRKDM4EGAALMNA
SCHEMBL30061304 0.79 AURKA (0.53) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL21053189 0.79 AURKA (0.53) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL21090663 0.79 MAPT (0.49) MAPTBRAFKDM4EGAAALDH1A1
SCHEMBL20766513 0.78 TEAD1 (0.80) MAPTTEAD1YAP1TNNI3KIDH2
SCHEMBL20767446 0.77 TEAD1 (0.62) MAPTTEAD1YAP1TNNI3KIDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
CN-111542315-B Benzosulfonyl compounds 维瓦斯治疗公司 2023-05-12 — — CN disclosed
EP-3691623-B1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS INC (US) 2022-10-05 — — EP disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 — — US disclosed
US-11192865-B2 Benzosulfonyl compounds VIVACE THERAPEUTICS, INC. (US) 2021-12-07 — — US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 — — US disclosed
US-20200354325-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-12 — — US disclosed
CN-111542315-A Benzosulfonyl compounds 维瓦斯治疗公司 2020-08-14 — — CN disclosed
WO-2019040380-A1 BENZOSULFONYL COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2019-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192865-B2 Benzosulfonyl compounds YAP1, TEAD2, TEAD1 MAPT 2341/4885TEAD1 3/4885YAP1 1/4885
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 MAPT 516/4885TEAD1 1/4885YAP1 9/4885
US-20200354325-A1 BENZOSULFONYL COMPOUNDS YAP1, TEAD2, TEAD1 MAPT 2341/4885TEAD1 3/4885YAP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback